Related Experiment Videos
[Fatal hepatic failure in a normally developed 5-year-old boy caused by VPA monotherapy]
Insights
Valproate (VPA) treatment can cause fatal liver failure and bleeding disorders, even in young, otherwise healthy children. This rare but severe risk highlights the need for careful monitoring during VPA therapy.
Area of Science:
- Pediatric Neurology
- Hepatology
- Pharmacovigilance
Background:
- Valproate (VPA) is a widely used antiepileptic drug.
- Established guidelines recommend VPA therapy for children over two years old, on monotherapy, and without other significant health issues.
- Despite these precautions, severe adverse events can occur.
Observation:
- A five-year-old boy with absence epilepsy developed fatal liver failure and intractable bleeding 16 weeks after initiating VPA monotherapy.
- The patient was previously healthy and met standard criteria for VPA treatment.
- This case illustrates a severe, unexpected complication of VPA therapy.
Findings:
- VPA monotherapy can lead to life-threatening hepatotoxicity and coagulopathy.
- Fatal outcomes are possible even when VPA is administered according to current safety recommendations.
- Approximately 100 deaths worldwide have been reported in association with VPA treatment.
Implications:
- Current VPA treatment guidelines may not fully mitigate the risk of fatal adverse events in pediatric patients.
- Healthcare providers must maintain a high index of suspicion for VPA-induced toxicity, regardless of patient profile.
- Further research into the mechanisms and risk factors for severe VPA toxicity is warranted to improve patient safety.
Abstract:
A five-year-old, normally developed boy who had been healthy except for an absence epilepsy prior to valproate (VPA) treatment died 16 weeks after the introduction of VPA-monotherapy due to liver failure and intractable bleeding disorder. This case emphasizes that the restriction of VPA-therapy to children of more than two years of age, on monotherapy, and without evidence of other diseases or retardation does not exclude fatal complications. Until today world-wide about 100 patients have died during VPA-treatment.